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Abstract
Liver transplantation (LT) for alcohol related hepatitis (AH) remains controversial. We 
convened a consensus conference to examine various aspects of LT for AH. The goal 
was not to unequivocally endorse LT for AH; instead it was to propose 
recommendations for programs that perform or plan to perform LT for AH. Criteria were 
established to determine candidacy for LT in the setting of AH and included the 
following: (1) AH patients presenting for the first time with decompensated liver disease 
that are non-responders to medical therapy without severe medical or psychiatric 
comorbidities (2) A fixed period of abstinence prior to transplantation is not required (3) 
Assessment with a multidisciplinary psychosocial team including a social worker and a 
addiction specialist/mental health professional with addiction and transplantation 
expertise.  Supporting factors include lack of repeated unsuccessful attempts at 
addiction rehabilitation, lack of other substance use/dependency, acceptance of 
diagnosis/insight with commitment of patient/family to sobriety and formalized 
agreement to adhere to total alcohol abstinence and counseling.   LT should be avoided 
in AH patients that are likely to spontaneously recover. Short- and long-term survival 
comparable to other indications for LT must be achieved.  There should not be further 
disparity in LT either by indication, geography, or other sociodemographic factors. 
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The restrictive and focused evaluation process described in the initial LT experience for 
AH worldwide may not endure as this indication gains wider acceptance at more LT 
programs.  Transparency in selection process is crucial with collection of objective data 
to assess outcomes and minimize center variation in listing. Oversight of program 
adherence is important to harmonize listing practices and outcomes.
  
SUMMARY OF RECOMMENDATIONS
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1. There should be efforts to standardize nomenclature and definition of alcohol related 
hepatitis (AH) with an emphasis on use of less stigmatizing terminology. (see Table 
1 and 2)  
2. Patients with severe AH may be assessed for corticosteroid therapy.
3. Select patients with severe AH that are unresponsive to medical management may 
be considered for liver transplantation.
4. Predicting response to therapy or pre-LT mortality is best achieved by assessing 
response over time (change in Model for end stage liver disease (MELD) score, Lille 
score or a combination of MELD score plus Lille).  Mortality is lower for those that 
have a Lille score <0.45, respond to therapy, have a declining bilirubin, or are 
abstinent and these patients may not require LT.
5. An inflexible period of abstinence prior to transplantation is not desirable. 
Acceptance for LT listing should be based upon the severity of liver dysfunction and 
a comprehensive psychosocial evaluation. (see Table 3)
Recommendations for LT for alcohol related hepatitis (see Figure 1 and Table 4)
A. The goals of LT for AH include:
1. Avoiding LT in patients who will recover without it
2. Avoiding futility and achieving short- and long-term survival comparable to other 
indications for LT 
3. Avoiding creation of further disparity in LT either by indication (versus other 
indications), geography, sex, race, insurance status or other sociodemographic factors.
4. Identification of LT candidates likely to have long-term abstinence
5. Incorporation treatment of alcohol use disorder (AUD) into pre and post-LT care
6. Consensus of paramedical and medical staff
B.  Criteria related to AH 
1. First presentation with decompensated alcohol-related liver disease 
2. Absence of severe uncontrolled medical or psychiatric comorbidities.















This article is protected by copyright. All rights reserved
C.  Criteria related to AUD
1. Establish acceptable risk of relapse by assessment with a multidisciplinary 
psychosocial team including a social worker and an addiction medicine specialist/ 
mental health professional with addiction and transplantation expertise.  
2. Assessment of coherent patient by addiction specialist (i.e. not intubated or floridly 
encephalopathic). 
3. Lack of repeated unsuccessful attempts at addiction rehabilitation.  
4. Lack of current other substance use/dependency.
5. Acceptance of ALD diagnosis with insight.
6. Commitment of patient to lifelong sobriety and support of sober caregivers to assist 
patient with abstinence goals.
7. Presence of close, supportive family members or caregivers
D.  Post LT requirements
1. Pre-LT confirmation of plan for AUD treatment after LT
2. Robust post-transplant monitoring for alcohol slips or relapse during post-LT clinic 
appointments to include direct interviewing of patient and caregivers about alcohol 
use.
3.  Routine monitoring of alcohol use (e.g. with Phosphatidylethanol (PEth), Urinary 
ethyl glucuronide) for at least 2 years, with frequency and duration individualized 
beyond this time period.
E. Center requirements
1. Transparency in the candidate selection process and structured collection of 
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2.  Ongoing support of abstinence that is integrated into post LT care such as 
concurrent follow-up by addiction specialist/mental health professional with addiction 
and transplantation expertise.
3. Oversight of program adherence to harmonize listing practices and outcomes.
Introduction
Alcohol is a major cause of liver disease worldwide(1) with alcohol related liver disease 
(ALD) being one the most frequent indication for liver transplantation (LT) in the US.(2) 
In addition to complications of cirrhosis and hepatocellular carcinoma, alcohol related 
hepatitis (AH) remains an important cause of liver related morbidity and mortality.    
Influenced by small trials showing acceptable outcomes in highly selected patients, 
transplantation for AH is increasingly performed in the US and elsewhere.(3-8) The 
percentage of patients transplanted for AH is likely underestimated; in a recent study 
only 35% of recipients transplanted for AH were accurately identified.(9) 
 
However, LT for AH faces substantial challenges. The medical criteria for AH LT must 
be carefully defined such that premature use of LT does not occur for patients likely to 
recover with supportive care. Additionally, in urgent cases of patients with AH, 
requirements for specific periods of significant sobriety pre-LT may vary.  The ability to 
provide the potential benefits of LT for AH patients must be balanced against the 
potential for alcohol relapse with resulting morbidity and mortality post-LT.  LT for AH 
may lead to disparities related to selection of candidates with AH for LT (may favor 
patients with resources) as well as impacting LT rates for other indications. While it is 
worthy to consider a more compassionate and thoughtful approach to LT for AH 
patients the shortened time frame for transplant evaluation in urgent AH cases makes it 
difficult even for experienced teams to accurately capture psychosocial aspects 
predictive of outcomes after LT in AH. The public and provider perception of LT for ALD 
continues to evolve and may not be as controversial as previously thought.(10-18)  
Further, there is a growing recognition that successful outcomes after LT also depend 
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demand a multidisciplinary team approach to the assessment, selection and post-LT 
longitudinal care of AH patients. 
To address these issues, Baylor University Medical Center in Dallas, Texas organized a 
two-day consensus conference (April 5-6, 2019) endorsed by International Liver 
Transplantation Society and American Society of Transplant Surgeons. Overall, 130 
participants including 82 physicians and over 60 transplant and non-transplant 
university and community programs were represented. Of these centers, 
representatives from 9 out of 12 ACCELERATE AH consortium centers attended.  A 
survey was not taken of which programs currently performed LT for AH, but varied from 
none to a few cases per year. Participants included addiction counselors, transplant 
surgeons, hepatologists, psychiatrists, coordinators (living donor, pre transplant, and 
post-transplant), nurses, program administration, social workers, insurance 
representatives and other staff. A draft of the manuscript was sent to all attendees for 
their collective input and comments.
There were several contentious points that were raised and a balanced discussion is 
presented in the submission. This included pros and cons of LT for AH, mandatory 
requirements for center reporting as well discussions regarding financial aspects. The 
goal was not to unequivocally endorse LT for AH; instead was to bring together a 
multidisciplinary group to discuss AH related practices at their centers and consider how 
clinical assessment, care, and selection for LT could be improved by the collective 
experiences. The consensus conference expanded on recent recommendations that 
“Liver transplantation may be considered in carefully selected patients with favorable 
psychosocial profiles in severe AH not responding to medical therapy.”(19)
General considerations: Alcohol related hepatitis
Definition:  Defining AH requires consideration of the pattern of alcohol use, clinical 
and laboratory presentation and exclusion of other etiologies of liver dysfunction. 
Guidance is provided by a recent consensus statement on behalf of National Institute on 















This article is protected by copyright. All rights reserved
uniformity to clinical trials and does not address LT.(20) (Table 1 and 2) Liver biopsy 
should be pursued in cases where the diagnosis of AH is unclear and/or if any 
alternative diagnosis may affect the treatment plan, especially with regards to eligibility 
for LT. Considering LT for AH does not obviate program requirements for chronic liver 
disease/cirrhosis related to alcohol which may follow a separate center specific 
pathway.
Incidence and mortality: Population based estimates in the US confirm an increase in 
the incidence of AH mirroring a global increase in ALD. (1, 21-23) There has been an 
increase among young adults, minorities and women. (21, 24-26) In national data, the 
age and gender standardized rate of ALD related mortality has increased by 3-fold in 
persons aged 25-34 (CDC accessed March 2019).  
Medical Therapy:  The proposed treatment algorithm in AH differentiates management 
based on disease severity.(27)  Treatment for AH includes supportive medical therapy 
in addition to abstinence from alcohol, management of withdrawal symptoms, nutritional 
support and consideration of corticosteroid therapy for definite and probable AH.  There 
is a need to accurately identify patients that are candidates for corticosteroid therapy, 
those ineligible for corticosteroids or non-responders to therapy as early as possible.   If 
corticosteroids are used, absence of response as defined by the Lille score should lead 
to their discontinuation. Several investigational compounds are under evaluation for 
patients with AH but their role in AH remains to be established.(28)   
Predictive models: Several predictive models assess treatment response and predict 
mortality within 1-6 months after diagnosis of AH (29-34).   Most models have high 
negative predictive value (predict those that will do well) and not necessarily identify all 
that will not survive.  A model combining a static component (MELD) with a dynamic 
model (Lille) may be useful to identify non-responders to medical therapy  and/or 
patients unlikely to recover (35). Extra hepatic complications most notably serious 
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Liver transplantation for alcohol related hepatitis 
Figure 1, Table 3 and 4 summarize recommendations from the consensus conference. 
The following sections discuss specific recommendations in more detail.
Ethical Considerations:  Liver transplantation balances three principles of justice: 
urgency, utility, and equity.  Urgency demands that organs go to the “sickest first.” AH 
typically have high MELD scores with 75% mortality at 6 months in those not 
responding to prednisolone.(33)  Utility demands that organs be given to patients in 
whom post-transplant outcomes will be acceptable.  Medically, AH patients compare 
favorably to other diagnoses, with acceptable post LT patient and graft survival rates.(5, 
39)  Equity mandates that we adopt principles of liver transplant allocation that are 
applied similarly to all liver diseases.   Where behaviors are responsible for primary liver 
disease requiring transplant or for graft loss (such as non-adherence) after transplant, 
allocation decisions should be made in a similar manner and not applied in a more 
stringent manner only to those with ALD or AH.(40) 
European and US Experience in LT for AH:  The initial experience in early “rescue” 
liver transplant in AH was the French/Belgian trial.(6)   Non-responders to medical 
therapy, defined as a Lille model of ≥ 0.45 or a worsening of MELD score at day 7 of 
therapy, were considered for rescue LT.   Candidates were selected using the following 
criteria: nonresponse to medical therapy, severe AH as the first liver-decompensating 
event, presence of close supportive family members, absence of severe coexisting or 
psychiatric disorders, and agreement to adhere to lifelong total alcohol abstinence. 
Complete consensus was required among four provider “circles” involved in patient care 
for LT approval.   Ultimately, 26 medical non-responders underwent LT.  A significant 
survival benefit at 6 months was observed (76.9% versus 23.1% for matched non-
transplanted patients). Survival after transplant was similar to random responder 
controls (85%).   Relapse rate was low; 10% overall had return to harmful drinking. (6, 
41). These results supported future evaluation in selected patients with severe AH 
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Studies in the US were subsequently pursued (3-8) As compared to the European 
experience where a prospective protocol was followed, the US experience was a mix of 
center specific experience and established protocols.  In one study, 20/94 patients 
(21.2%) with severe AH refractory to medical therapy were approved for LT and 9 
ultimately underwent LT (3).   Eight of the 9 patients (89%) survived more than 6 
months compared to 30% of the patients that did not undergo LT.   Two patients had 
alcohol relapse, neither leading to adverse outcomes.  A second pilot study compared 
the outcomes of LT for AH and alcohol associated cirrhosis (AC). At a median follow-up 
of 532 days (IQR 281-998 days), rates of alcohol use and harmful drinking post-LT were 
similar for AH and AC at 28% and 24%, respectively (p=0.80).(7)   ACCELERATE-AH, 
the largest US experience in LT for AH, was a retrospective review from 12 centers, 
including the two centers that had published the pilot studies.(5)  Each center had their 
own “protocol” and while there were some differences between sites in terms of 
inclusion/exclusion criteria, there were many similarities.(5)  Of the 432 patients 
evaluated, 155 (35.9%) were accepted as candidates with rates ranging from 13-100% 
across centers.(5) Psychosocial concerns were the predominant reason for denial of 
listing for LT.   Overall survival after LT for AH was excellent with 1 and 3-year survival 
rates of 94% (95% CI, 89-97%) and 84 % (95% CI, 75-90%), respectively.    In patients 
surviving to discharge, 28% resumed alcohol use with 11% returning to harmful 
drinking.    Alcohol relapse post-LT had an adverse impact on survival at 3 years when 
compared with abstainers (75% vs. 97%, respectively, p=0.03) and 7 of the 9 deaths 
that occurred after one-year were alcohol related.    More than 10 drinks per day, non-
THC substance use, prior alcohol related legal difficulties , and more than 1 failed 
alcohol treatment attempt were associated with sustained alcohol use after LT.(43) No 
long-term follow-up data are available.  
Arguments in favor of LT for AH: First, LT for ALD has been performed since the 
1960s.(44)   LT for appropriately selected AH prevents premature mortality.  In severe 
AH, failure of medical therapy can be predicted early in the patient’s course and is 
associated with a 6-month survival around 30%. (33) As most deaths occur within 2 
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patients can participate in following LT.  Given the stringent criteria used to select AH 
LT candidates thus far, relapse rates after LT are similar for patients transplanted for AH 
versus ALD with cirrhosis.(45-49)  Third, LT for those with AH ensures equity of access 
to life-saving transplant, as in other liver diseases. As an example, LT is offered to 
obese individuals with NASH even without demonstration of weight loss pre-LT and is 
also offered to carefully selected patients with acute liver failure following a suicide 
attempt due to medication overdoses with uncontrolled psychiatric disease.   Finally, 
concern that early LT for AH may decrease organ donation is contrary to a survey 
showing that most potential organ donors were supportive or neutral with regard to this 
new indication (16). 
Concerns about LT for AH: First, criteria advocated for LT for AH may not be uniformly 
adhered to at all centers. There may be a disconnect between the restrictive and 
focused evaluation process described in the initial experience with LT for AH and its 
wider acceptance elsewhere across LT programs.(6) There is already wide variation in 
acceptance of AH for LT and clarity on what criteria are necessary to ensure good 
outcomes is lacking.  Second, relevant outcomes after LT may be inadequately 
captured.  Although survival rates were acceptable, deaths due to fungal infection were 
frequent in the European experience with most deaths due to infection within 2 weeks 
after LT.  Survival at 6 months for recipients (77%) was much lower than that for ALD 
reported to UNOS (94%).  Variation in medical management (e.g. steroid use) among 
centers may play a role.  Third, the cumulative probability of any alcohol use after LT 
was 25%, 30% and 34% at 1, 2 and 3 year.(5) Patterns of alcohol use were worrisome 
with median time to first drink of 160 days (79-346), sustained alcohol use in 38%, and 
binge or frequent drinking in 42%.  Hence, there is an obvious need for predictive tools 
to identify patients at high risk of relapse especially those with harmful drinking patterns 
(42). Fourth, high MELD score at LT, common among those presenting with AH, may tilt 
the balance toward “bending the rules” to transplant these recipients.  It is unavoidable 
that competition between programs will loosen acceptance criteria.  The requirements 
for acceptance should be the same for all patients, regardless of social or financial 















This article is protected by copyright. All rights reserved
women undergoing LT for AH is low (5). Hence there may be unrecognized barriers to 
LT for certain subgroups.  
Psychosocial perspective in LT for AH (Table 3)
In addition to being responsible stewards and “gatekeepers,” psychosocial assessors of 
transplant candidates often create intervention or treatment plans to mitigate risk for 
potentially poor outcomes.  For patients with an AUD and short duration of sobriety this 
commonly involves engaging the patient in addiction rehabilitation.  However, in the 
urgent AH scenario because there is no time to provide pre-LT rehabilitation, LT teams 
rely on more stringent selection criteria for AH candidates in hope of preventing poor 
outcomes post-LT.
Challenges in Evaluation of AUD in an urgent setting:   Evaluation and treatment of 
AUD that coexists in patients with AH is crucial. During an expedited evaluation, AUD 
may be inadequately addressed, (2) assessment and selection occurs in a limited and 
expedited time and (3) treatment for AUD, a chronic disorder with need for ongoing 
management, is often not accorded priority.  In a life-threatening medical condition, it is 
difficult to expect a patient to contemplate hypotheticals (e.g. lifelong abstinence, 
willingness to attend addiction rehabilitation, adherence to transplant directives) with 
no/little evidence they will/can do so.  In addition, there is no opportunity to reassess a 
candidate’s response after addiction treatment initiation.  Patients and families may try 
to manage impressions about or minimize their alcohol use history. Patients may be 
difficult to interview due to being in denial or feeling ashamed, guilty, overwhelmed, 
scared, or in pain.  In this context, establishment of an effective therapeutic relationship 
to management AUD can be challenging.
Necessary Components of the psychosocial assessment:  Optimally the patient 
should be directly interviewed by the social work and mental health and/or addiction 
professionals.  Thus, the request for these evaluations should occur early in the hospital 
course prior to the development of encephalopathy.   The composition of the mental 
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strength of recommendations. Transplant centers considering AH transplant should 
have in place a multidisciplinary psychosocial team composed, at a minimum, of a 
transplant social worker and a mental health professional preferably with addiction and 
transplant experience.  An addiction specialist may be helpful in ensuring AH patients 
receive the full spectrum of AUD care.  Psychometric scales and instruments can be 
used to aid the collection and integration of data but should not be used to determine 
candidacy. Scales may be helpful for tracking treatment response and anticipating 
further treatment needs.  Collateral information should be sought from family members, 
LT team members and other clinical care providers to provide a comprehensive picture 
of the patient’s history.  Active family or caregiver support is paramount for current and 
future care.  Biochemical markers may also be needed to corroborate drinking history. 
Patients with AUDs often have other psychiatric co-morbidities. In circumstances where 
an AH candidate has a co-morbid other psychiatric disorder additional evaluation by a 
psychiatrist is indicated. That may be a decision taking place at the program level based 
on (1)  the comfort and psych expertise of the referring team and social worker, (2) 
potential meeting of a threshold on a standardized scale (e.g. SIPAT) and (3)  resource 
availability.
Factors associated with risk for post-LT alcohol use: Until a larger experience is 
developed with AH alcohol use outcomes, the LT field draws on the substantial 
experience of predictors of relapse for ALD LT and from the general non-LT population 
of AUD patients. It is critical to recognize that the presence of a factor associated with 
alcohol use means the likelihood of alcohol use is greater, not that it is certain.(5, 7, 50-
53)  Whether a single criterion or cumulative factors are used to determine AH LT 
candidacy is not settled. Proposed criteria or risk scores have high negative predictive 
value and predict those who will not return to harmful patters of alcohol use rather than 
identify those that will.(54)
Duration of sobriety: Aside from allowing a period of observation to ensure an AH 
patient has adequate time to respond to medical therapy avoiding preemptive LT, the 
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patient’s ability to maintain sobriety is ill-conceived.  In AH such a mandated wait could 
allow the patient to deteriorate increasing the surgical risk, but each month sober only 
incrementally reduces risk.  There is limited support for a specific 6-month cut point(51)  
Further, in the natural history of AUD, stable abstinence is measured in years not 
months.  Recently, expert guidelines no longer recommend a fixed period of abstinence 
prior to transplantation  (27, 55) and have stopped listing AH as an absolute 
contraindication (55) to LT contrary to the recommendations from the preceding decade 
(56). 
Post transplantation needs: After transplantation, the AH LT recipient should be 
assisted in beginning addiction treatment as soon as medically feasible. This critical 
requirement should not be lost among the other post-LT care needs. Psychosocial 
evaluation and treatment should be integrated in the flow of post LT care and should be 
mandated by center.  There should be agreement of LT team to facilitate post-LT 
participation in addiction treatment and rigorous collection of alcohol use outcome data.  
To improve adherence, treatment and monitoring expectations should be developed 
prior to LT.  LT teams may need significant assistance from their social work and 
behavioral health providers to overcome potential barriers to addiction treatment; lack of 
local care, lack of adequate or appropriate resources, lack of monitoring (biochemical or 
collateral) and insurance issues. 
Living donor transplantation for AH
AH patients listed for deceased donor liver transplantation may also be considered 
candidates for living donor liver transplantation.  The medical risks to the donor are the 
same regardless of recipient etiology of disease.  However, there may be increased 
psychological risks to donors for recipients with AH related to relapse and graft loss 
especially long term once routine follow up ends.  Adherence to autonomy for both the 
donor and recipient through the process of informed consent and disclosure is equally 
important.   With AH, the recipient’s etiology of disease and potential for relapse might 
affect the donor candidate’s decision about donation so centers must have a policy in 
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must ensure that the urgency of need is not interfering with information disclosure, 
processing, or the ultimate decisions of donors.   The informed consent process also 
requires voluntariness in decision-making.  Voluntariness is defined as the absence of 
coercion, unwarranted persuasion or undue manipulation. Potential living donors for AH 
recipients may be victims of unwarranted persuasion because they are asked to decide 
in a time pressured manner to help a loved one who is at imminent risk of dying.  All 
transplant centers are required to provide an independent living donor advocate for 
living donor evaluation.  For individuals considering living donation to AH recipients, the 
independent living donor advocate, along with the rest of the donor evaluation team, 
must ensure that the decision meets the standards of voluntariness.  
Payer coverage
The 6-month rule has been enforced and reflected in medical policy set forth by most 
payers.  With recent data and a more definitive set of professional statements and 
modification of specific institutional criteria referring the 6-month rule, changes in payer 
coverage policies must follow. This would result in a coverage that better reflects 
evolving standard of care. A commitment by payers for addiction counseling post 
transplantation is equally important. From a resource allocation standpoint advocating 
for insurance payer coverage for AUD treatment is crucial.  In addition, centers may 
experiment with unique ways of bridging coverage gaps, resource deficits, and 
insurance disparities.  These may include telemedicine, provider-to-provider 
consultation models, collaborative care models, cross-disciplinary training, and 
community outreach efforts.  Programs need to invest not only in coordinators and 
nutrition specialists for medical management but also addiction specialists.
Payer limitation of coverage continues to be an issue. There has been increased 
attention to mental health benefits as there continues to be concern about the adequacy 
of coverage under most health plans.   The Mental Health Parity Act (MHPA) of 1996 
aimed to prevent group health plans and health insurance issuers that provide mental 
health or substance use disorder (MH/SUD) benefits from imposing less favorable 
benefit limitations on MH/SUD benefits than on medical/surgical benefits. Mental Health 
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and adds significant new protections, such as extending the parity requirements to 
substance use disorders. It was amended by the Health Care and Education 
Reconciliation Act of 2010 (collectively referred to as the “Affordable Care Act”) to also 
apply to individual health insurance coverage. A concerted effort by national liver 
societies and patient advocacy groups may be needed to harmonize this coverage 
across centers.
Role of the transplant center
LT centers are likely only seeing the tip of the iceberg’ with many AH patients never 
being evaluated or even discussed with LT centers. Transparency in center practices 
and oversight is paramount. Oversight of structural components of the program are 
needed. This includes presence of adequate psychosocial and addiction personnel at 
centers undergoing LT for AH, monitoring of pre/post-transplant outcomes and 
structured data collection.  The transplant community needs to consider mandated 
collection of AH specific elements and centers be open to sharing center specific 
practices to improve outcomes. (Table 5)  Local or regional review boards may need to 
be involved to assure transparency and third party adjudication or oversight, such as 
that provided by UNOS may be needed. 
The need to streamline processes and the anticipated burden to the system 
(psychosocial assessments, expansion of team, increased hospital volume) is clear.   
Centers need to invest and ensure having mental health professionals/addiction 
specialists available not only for pre transplant evaluation, but also for post-transplant 
assessment and active follow up after discharge.  Provider team frustration and burnout 
may feature prominently as more patients with AH are evaluated. This will require teams 
to monitor and address the mental health, burnout, and cynicism of their providers and 
staff.  Teams need to insist on and expect psychosocial providers to meet frequently 
and thoroughly collaborate among themselves. 
Expansion of LT for AH will affect center activity. Issues may arise about the number of 
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how LT for AH might impact LT for other indications, particularly within the new acuity 
circle policy.   There may be financial gain in transplanting patients with AH; a high 
MELD patient with AH may inherently have better short-term outcomes than high MELD 
patients without AH though further data is needed. This could be partially mitigated by 
requiring centers to meet 2 year survival criterion for AH, as relapse to harmful alcohol 
use typically leads to deaths beyond the 1st year.
Competition between centers for these patients is a concern. Within a region, there may 
be market pressures for other centers to follow suit. Hence, failure to offer transplant for 
patients with AH may reduce referrals for this and other indications.  In addition, referral 
physicians often view an “active plan” such as transplant as a better option than a 
“passive plan,” i.e., supportive care.  So, the perception of the transplant center within 
the community as an “aggressive” or “forward thinking” or “cutting edge” center plays 
heavily on the treatment plan for these patients. There is a clear need for community 
education on this topic so that limited LT center resources can be optimally used and to 
limit patient dissatisfaction and associated provider burnout/cynicism.
It needs to be reiterated that only a very small number of patients is expected to fulfill 
this very strict criteria.
Conclusion
LT for ALD has evolved over the last 40 years, starting from an absolute 
contraindication to an accepted routine reason for LT. Following in its footsteps, LT for 
AH remains contentious. With a measured approach that collectively considers and 
respects the perspectives of all stakeholders in the transplant process, consensus and 
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Figure 1: Listing criteria and program components for LT for AH
AH: alcohol related hepatitis; AUD: Alcohol use disorder; PEth: Phosphatidylethanol; 
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Table 1: Suggested changes in nomenclature 
 
Suggested Current 
Alcohol related liver disease Alcoholic liver disease 
Relapse Recidivism 
Alcohol related hepatitis Alcoholic hepatitis 




















































Table 2: Defining alcohol related hepatitis, modified from NIAAA AH clinical trial 
definition (Crabb et al Gastroenterology 2016) 
 
Definition Clinical entity with rapid 
onset of jaundice with elevated AST in 
background of heavy alcohol use. 
Pattern of alcohol use Heavy alcohol use for >6 months, <60 days 
of abstinence before onset of jaundice. 
Supporting features  
Biopsy steatohepatitis, cholestasis, severe fibrosis 
Presentation malaise, tender hepatomegaly, 
decompensation 
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Exclude Drug induced liver injury, biliary obstruction, 
viral hepatitis, autoimmune liver disease, 
Wilson disease 
Spectrum  AH versus acute on chronic liver failure 
Presence of cirrhosis 
Definite Clinical and biopsy proven 
Probable Clinical and exclude competing 
Possible 
Biopsy recommended 
Clinically diagnosed but with potential 
confounding factors (e.g. pt denies alcohol) 










Table 3: Psychosocial domains to be assessed in AH transplant candidates.  
Most of these predictors are for sustained or harmful relapse (not slips). 
Domain Assessed/Questions Asked Factors that May Predict Relapse 
1. Alcohol Use History  
 Length of use over time, when did 
use start, consumption patterns, 
 Younger age at onset of drinking 
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context of use, periods of abstinence 
 Diagnostic criteria for alcohol use 
disorder (reference DSM-V) 
 Problems with cravings/urges to drink 
 Sobriety attempts- voluntary and 
mandated 
 Alcohol use treatment history- types 
of treatment tried, sobriety duration 
after treatment, experiences with 
treatment, successes and failures.  
 Attitudes towards alcohol use: assess 
insight and acceptance of alcohol as 
problem, readiness for change, 
commitment to sobriety and alcohol 
treatment 
 Recent changes in alcohol use in 
relation to life stressors with 
assessment of potential modifiable 
behaviors and situations. 
transplant consideration 
 Multiple failed rehab attempts 
 History of legal problems due to 
alcohol use 
 Shorter pre-transplant abstinence 
 Lack of insight into alcohol use 
problems 
 Lack of acceptance of alcohol use 
as a problem 
 Lack of candor and/or deceptive 
behavior with respect to transplant 
team 
 Severe AUD 
 
2. Other Substance Use History  
 Length of use over time, onset of use, 
consumption patterns, context of use 
 Diagnostic criteria for substance use 
disorder 
 Treatment history (as above) 
 Active, untreated polysubstance 
use (except marijuana) 
 Comorbid tobacco use, relapse to 
tobacco use 
3. Mental Health History  
 History of psychiatric diagnoses 
 Presence of suicide attempts 
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 History of any mental health 
treatment, including inpatient 
treatment 
 Response to mental health treatment 
 Recent suicide attempt 
 
4. Treatment Adherence History  
 Past and current adherence to 
medical and mental health treatment 
plan 
 Ability to understand and adhere to 
transplant treatment plan 
 History of extensive nonadherence 
to medical or mental health 
treatment 
 
5. Social Criteria  
 Sober support system 
 Number of support persons, 
relationship to patient, ability to 
dedicate time/resources to medical 
and mental health care 
 Lack of sober support network 
 Only 1 sober support person 
Optimal Assessment Criteria 
1. Awake, alert patient (not comatose, altered, or intubated), able to be directly interviewed 
2. Psychosocial team assess patient first to obtain unbiased evaluation of above factors. 
3. Consistent history and commitment verbalized by patient 
4.  Multiple assessments over time 
5. Active involvement and sober support by family/caregivers 





























Table 4: Listing criteria and program components for LT for AH 





First presentation with 
decompensated AH 
No prior liver related hospitalization 
 Absence of severe medical 
comorbidities 
 Frailty, debility and multiorgan failure 
 No other contraindications to LT 
 Non-response to medical 
therapy. 
 Contraindications: disease severity, 
multi organ failure, infection, renal 
failure and low likelihood for response 
 Consider non-responders using Lille 
score >=0.45 or worsening of liver 
function by d4 or d7 





Establish acceptable risk of 
relapse as assessed by a 
multidisciplinary psychosocial 
team composed of a social 
worker and at least one 
addiction specialist.   
 
 Not intubated 
 Consider independent team of 
specialists in addiction, social 
workers, and mental health providers 
 Ideally first member of LT team to 
evaluate 
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for regional or local review 
 Direct assessment of patient 
possible by addiction 
specialist  
 i.e. not intubated or floridly 
encephalopathic. 
 A maximum of 1 prior failed 
attempt at rehabilitation. 
 
 Lack of other active 
substance use/dependency or 
active untreated psychiatric 
disorder 
 
 Acceptance of 
diagnosis/insight 
 
 Commitment of patient/family 
to sobriety and formalized 
agreement to adhere to 
lifelong total alcohol 
abstinence 
Establish contract and participation in 
addiction rehabilitation following 
transplant 
 Presence of close, supportive 





Consensus of paramedical 
and medical staff 
 
Consider blinded voting in committee 
deliberations 
Consider absolute consensus 
Program 
components 
Transparency in selection 
process 
 Creation of internal policies / 
procedures consistently followed by 
the transplant program  
 Willingness to share, publish or have 
policies/procedures reviewed by 
outside agents  
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experiences with AH in CONSORT 
flow diagram including those 
assessed for eligibility, excluded and 
reasons, treatment responders, 
transplant outcomes, and elements of 
selection criteria 
 Enhanced reproducibility by use of 
standard definitions and common data 
elements 
 Consistent and timely structured data 
reporting 
 Independent psychosocial 
assessment 
 Mental health professional with 
addiction background/training 
 Mental health professional familiar 
with transplant process 
 Structured Post LT follow up 
mechanism in place 
 Documentation of AUD management 
plan pre and post-LT 
 Dedicated addiction specialist/mental 
health professional for longitudinal 
management 
 Commitment for regular monitoring for 
alcohol use Phosphatidylethanol 
(PEth), Urinary ethyl glucuronide 
 Structured monitoring program for 
post-transplant alcohol relapse and, in 
the event of alcohol relapse, provide 
resources to assist the patient in 
recovery 
 Team mental health  Consider formal addiction education 










































































Table 5: Data collection in programs performing LT for AH 
 
Timing Main component Sub component 
Pretransplant AH definite, probable, possible 
 Number with AH  
 Number evaluated  
 Number listed  
 Medical and psychosocial 
Characteristics of evaluated 
not listed vs listed 
Gender, race, MELD, 
insurance 
 Medical treatment Steroids, other 





 Accurate coding for AH  
 AUD diagnosis Mild, moderate, severe 
 Prior AUD treatment Types of AUD treatment 
previously used 
 Explant and Biopsy 
characteristics 
 
 Comorbid psychiatric and/or 
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 Other substance use  




mental health professional 
 Routine Testing Alcohol biomarker testing: 
Phosphatidylethanol (PEth), 
Urinary ethyl glucuronide 
 Pattern of alcohol use Slip, relapse, heavy 
Post LT Documentation of AUD 




 Documentation of EtG or 
PEtH testing 
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